What is the best treatment for a 72-year-old male (YOM) with Alzheimer's disease presenting with anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The best treatment for a 72-year-old male with Alzheimer's disease presenting with anxiety involves a combination of non-pharmacological and pharmacological approaches, with a focus on selective serotonin reuptake inhibitors (SSRIs) as the preferred pharmacological option due to their favorable side effect profile in elderly patients, as recommended by the most recent and highest quality study 1.

Non-Pharmacological Interventions

Non-pharmacological interventions should be tried first, including:

  • Establishing a consistent daily routine
  • Creating a calm environment
  • Using music therapy
  • Engaging in regular physical activity
  • Providing caregiver education on communication techniques These interventions can help alleviate anxiety symptoms and improve the patient's quality of life, as suggested by earlier studies 1.

Pharmacological Treatment

If non-pharmacological interventions are insufficient, pharmacological treatment may be considered. SSRIs like sertraline (starting at 25mg daily, gradually increasing to 50-100mg daily if needed) or escitalopram (5mg daily, potentially increasing to 10mg) are generally preferred due to their favorable side effect profile in elderly patients, as supported by the most recent study 1.

  • Benzodiazepines should be avoided due to increased risk of falls, confusion, and potential worsening of cognitive function.
  • Antipsychotics should only be used with caution for severe anxiety with agitation that poses safety risks, at the lowest effective dose and for the shortest duration possible.

Monitoring and Review

Regular monitoring for side effects and treatment efficacy is essential, with medication reviews every 3-6 months. This approach balances anxiety management while minimizing adverse effects in elderly patients with cognitive impairment, as emphasized by the latest expert recommendations 1.

From the FDA Drug Label

Buspirone hydrochloride tablets are indicated for the management of anxiety disorder or the short-term relief of the symptoms of anxiety. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms

The best treatment for a 72-year-old male with Alzheimer's disease presenting with anxiety is buspirone.

  • Key points:
    • Buspirone is indicated for the management of anxiety disorder.
    • It has been shown to be effective in patients with generalized anxiety disorder (GAD) and coexisting depressive symptoms.
    • There is no specific information in the provided drug labels regarding the use of buspirone in patients with Alzheimer's disease, but it may be considered as a treatment option for anxiety in this population.
    • The safety and efficacy profiles for elderly patients (mean age = 70.8 years) were similar to those in the younger population (mean age = 43.3 years) in one study 2.
    • However, greater sensitivity of some older patients cannot be ruled out, and the administration of buspirone to patients with severe hepatic or renal impairment cannot be recommended 2.

From the Research

Treatment Options for Anxiety in Alzheimer's Disease

The treatment of anxiety in a 72-year-old male with Alzheimer's disease requires careful consideration of the available evidence.

  • Antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are considered first-line treatments for anxiety in the elderly 3.
  • SSRIs such as sertraline and escitalopram are preferred due to their favorable pharmacokinetic profiles and efficacy in treating anxiety in older adults 4.
  • Buspirone may be an option for relatively healthy older adults, but its efficacy in elderly populations with Alzheimer's disease is not well established 3, 4.
  • Other treatment options, such as mirtazapine and vortioxetine, may be considered, but their use in elderly populations with Alzheimer's disease requires careful evaluation 3, 4.

Avoiding Certain Medications

Certain medications should be avoided or used with caution in the treatment of anxiety in elderly populations with Alzheimer's disease.

  • Benzodiazepines and beta blockers should generally be avoided due to their potential for adverse effects and interactions 3.
  • Antipsychotics and mood stabilizers should also be avoided due to their risk of problems in both the long and short term, including increased mortality in elderly patients with dementia 3.
  • Tricyclic/tetracyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) may be effective, but their side effect and safety profiles are suboptimal, making them less desirable options 3.

Considerations for Alzheimer's Disease

The treatment of anxiety in Alzheimer's disease must also consider the complexities of the disease itself.

  • Depression is common in Alzheimer's disease, and antidepressants may be used to treat both depression and anxiety 5, 6.
  • However, the efficacy of antidepressants in treating depression in Alzheimer's disease is limited, and their use may be associated with adverse effects 5, 6.
  • Future studies are needed to identify effective and multimodal pharmacological treatments that efficiently treat anxiety and depression in Alzheimer's disease 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacological Management of Anxiety Disorders in the Elderly.

Current treatment options in psychiatry, 2017

Research

Sertraline for the treatment of depression in Alzheimer disease.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.